Avlar BioVentures Ltd.
This article was originally published in Start Up
Executive Summary
The UK's Avlar BioVentures is not concerned about the overshadowing popularity of Internet stocks or the present volatility of biotech stocks. It has amassed a pool of patient capital for European biotech start-ups. Avlar BioVenture's new seed fund is just completing a second closing that will bring the total raised to 20 million pounds sterling.